Cardiorentis is a biopharmaceutical company, developing drug therapies for the treatment of acute heart failure and related cardiovascular diseases. The Company develops TRUE-AHF, an ularitide, which is an intravenous infusion treatment for acute heart failure; and SIRIUS I and II, a safety and efficacy study of an intravenous placebo controlled randomized infusion of ularitide in a prospective double–blind study in patients with symptomatic and decompensated chronic heart failures. Its disease-based technology platform includes protein biology to identify novel targets; design small molecule compounds and peptides for healthcare markets.
Who are Cardiorentis key executives?
Cardiorentis's key executives are Reto Wittwer, Stefan Mazgareanu and Markus Meyer.
Who are Cardiorentis competitors?
Competitors of Cardiorentis include CTI BioPharma, Acticor Biotech and Palatin Technologies.
Where is Cardiorentis headquarters?
Cardiorentis headquarters is located at 74 Steinhauserstrasse, Zug.
Where are Cardiorentis offices?
Cardiorentis has an office in Zug.
How many offices does Cardiorentis have?
Cardiorentis has 1 office.
Receive alerts for 300+ data fields across thousands of companies